正大企业国际2024中期报告

CHIATAIENTERPRISESINTERNATIONALLIMITED 正大企业国际有限公司 IncorporatedinBermudawithmembers’limitedliability•StockCode:3839 于百慕大注册成立之成员有限责任公司•股份代号：3839 INTERIMREPORT2024中期报告 Contents 目录 2ManagementDiscussionandAnalysis 管理层讨论及分析 6ReportonReviewofInterimFinancialReport 中期财务报告之审阅报告 8ConsolidatedStatementofComprehensiveIncome 综合全面收益表 10ConsolidatedStatementofFinancialPosition 综合财务状况表 12ConsolidatedStatementofChangesinEquity 综合权益变动表 14CondensedConsolidatedStatementofCashFlows 简明综合现金流量表 15NotestoInterimFinancialReport 中期财务报告附注 31OtherInformation 其他资料 35CorporateInformation 公司资料 MANAGEMENTDISCUSSIONANDANALYSIS 管理层讨论及分析 GROUPRESULTS TheGrouphastwolinesofbusiness:biochemicalbusinessandindustrialbusiness.Thebiochemicalbusinessfocusesonchlortetracycline(“CTC”)andanimalhealthproducts,andis 集团业绩 本集团从事生化业务及工业业务。生化业务专注于金霉素及动保化药产品，并由本集团之附属公司营运。此业务为本集团所有的综合收入。工业业务包含本集团 carriedonbyGroupsubsidiaries.Thisbusinesssegmentaccounts 于ECIMetroInvestmentCo.,Ltd（. 及其附属公司，统称 foralloftheGroup’sconsolidatedrevenue.TheindustrialbusinesscomprisestheGroup’sinterestsinitsjointventureECIMetroInvestmentCo.,Ltd.(togetherwithitssubsidiaries,“ECIMetro”)anditsassociateZhanjiangDeniVehiclePartsCo.,Ltd.(togetherwithitssubsidiaries,“ZhanjiangDeni”).TheresultsoftheGroup’sindustrialbusinessareincorporatedintheconsolidatedstatementofcomprehensiveincomeasshareofprofitsandlossesofjointventureandassociate. Forthesixmonthsended30June2024(“1H2024”),theGroup’srevenueincreased30.4%toUS$107.98million(forthesixmonthsended30June2023(“1H2023”):US$82.81million).However,overallgrossprofitmargindecreasedfrom20.0%in1H2023to16.7%in1H2024mainlyduetoanincreaseintradingbusinesswhichhasalowerprofitmargin. ProfitattributabletoshareholdersoftheCompanywasUS$1.96millionin1H2024,adecreaseof3.2%comparedtoUS$2.03millionin1H2023. Basicanddilutedearningspersharewereboth0.8UScents(1H2023:0.8UScents).TheBoardofDirectorsoftheCompanyresolvednottodeclareaninterimdividendforthesixmonthsended30June2024(1H2023:Nil). BUSINESSREVIEW Biochemical Wegenerateourrevenuemainlyfromthemanufactureand/orsaleofCTCproducts(CTCPremixandCTCHCL)andanimalhealthproducts.CTCproductsareantibioticsusedtopreventorcureanimaldiseases.Ouranimalhealthproducts,ontheotherhand,aremainlypreventivedrugsforlivestockdiseases.Inthepastfewyears,wehavebeenstrategicallybroadeningourproductportfoliotocoverrelatedveterinaryproducts.Ofthesenewofferings,somewemanufactureandsale,andsomewesourceandtrade.TheGroup’smajorcustomersincludefarms,pharmaceuticalcompanies,tradingcompaniesandfeedmills. “ECIMetro”）的合营企业权益及于湛江德利车辆部件有限公司（及其附属公司，统称“湛江德利”）的联营公司权益。本集团工业业务的业绩载列于综合全面收益表内的应占合营企业及联营公司溢利及亏损。 截至二零二四年六月三十日止六个月（“二零二四年上半年”），本集团的收入上升30.4%至1亿798万美元（截至二零二三年六月三十日止六个月（“二零二三年上半年”）：8,281万美元）。然而，整体毛利率从二零二三年上半年的20.0%下降至二零二四年上半年的16.7%，主要由于较低利润率的贸易业务增加所致。 二零二四年上半年本公司股东应占溢利为196万美元，较二零二三年上半年的203万美元下降3.2%。 每股基本及摊薄溢利均为0.8美仙（二零二三年上半年：0.8美仙）。本公司董事会决议不派付截至二零二四年六月三十日止六个月的中期股息（二零二三年上半年：无）。 业务回顾 生化业务 我们的收入主要来自制造及╱或销售金霉素产品（金霉素预混剂及盐酸金霉素）和动保化药产品。金霉素产品为用作预防或治疗动物疾病的抗生素。而我们的动保化药产品主要是用作家畜疾病的防治药。近年，我们一直战略性地扩大我们的产品系列，以涵盖相关的兽药产品。在这些新产品中，一部分我们制造及销售，一部分我们采购和贸易。本集团的主要客户包括养殖场、制药公司、贸易公司及饲料加工厂。 In1H2024,theGroup’srevenuefromthebiochemicalbusinessincreased30.4%toUS$107.98million(1H2023:US$82.81million).Oursalesmixchangedinlinewithourstrategicbusinessdirection.RevenuecontributionfromCTCproductsdecreasedfrom48%in1H2023to33%in1H2024,whilerevenuecontributionfromanimalhealthproductsincreasedfrom52%in1H2023to67%in1H2024. Ourasset-lighttradingbusiness–theexpandingsegment–hasalowerprofitmarginrelativetoourmanufacturingbusiness.Asaresult,overallgrossprofitmarginreducedfrom20.0%in1H2023to16.7%in1H2024.Nevertheless,contributionfromourbiochemicalbusinessimprovedin1H2024. Industrial TheGroup’sindustrialbusinessisconductedthroughECIMetroandZhanjiangDeni. ECIMetroisprincipallyengagedinthesale,leasingandservicingofCaterpillarmachineryequipmentinwesternChina.TheexcavatormarketinChinahadbeenimpactedbyadeclineinconstructionmachinerydemandinthepastfewyears.In1H2024,accordingtotheChinaConstructionMachineryAssociation,excavatorsales,inunitterms,acrosstheentiremarketrecordedamodest4.7%increasewhencomparedtothatin1H2023.Althoughwewereabletomaintainourvolumemarketsharein1H2024,ourrevenuefromsalesofexcavators,powersystemandsparepartsdecreasedduetointensecompetition.Salesofsmallandmedium-sizedconstructionmachinerywerealsocontinuouslychallengedbydomesticbrandsinChina.Asaresult,forthesixmonthsended30June2024,ourshareofprofitofjointventuredeclinedfromUS$2.61millionin1H2023toUS$0.11millionin1H2024. ZhanjiangDeniisprincipallyengagedinthemanufactureandsaleofautomotiveparts,whicharemainlysoldtoautomobileandmotorcyclemanufacturers.AccordingtotheChinaAssociationofAutomobileManufacturers,Chinaautomobilesalesin1H2024increasedby6.1%whencomparedtothatin1H2023.Ontheotherhand,accordingtoChinaChamberofCommerceforMotorcycle,Chinamotorcyclesalesin1H2024was2.9%lowerthanthatin1H2023.Forthesixmonthsended30June2024,ourshareofprofitofassociateremainedstableatUS$1.16million(1H2023:US$1.04million). 二零二四年上半年，本集团生化业务的收入上升30.4%至1